Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: J Neurooncol. 2010 Jan 9;99(1):73–80. doi: 10.1007/s11060-009-0103-2

Table 3.

Effect of EIAC treatment and UGT1A1*28 genotype on the pharmacokinetics of CPT-11 and its metabolites

Cohort A (non-EIAC), 125 mg/m2 Cohort B (EIAC), 400 mg/m2
All patients
(n = 15)		 6/6 (n = 5) 6/7 (n = 8) 7/7
(n = 2a)		 All patients
(n = 12)		 6/6 (n = 3) 6/7 (n = 7) 7/7
(n = 2a)
CPT-11
 Cmax (ng/ml) 1035 ± 272 1038 ± 314 901 ± 285 1318 3361 ± 943 3837 ± 1001 3378 ± 438 2589
 t1/2 (h) 6.27 ± 2.38 7.32 ± 4.26 6.05 ± 0.80 5.51 5.61 ± 0.91 5.33 ± 0.16 5.52 ± 1.00 6.34
 AUC (ng/ml h) 6890 ± 2448 5458 ± 2030 7322 ± 2885 9431 19449 ± 2966 21296 ± 5499 18697 ± 1484 19170
 Cl (1/h/m2) 20.8 ± 8.9 26.4 ± 12.1 19.0 ± 5.8 13.9 20.9 ± 2.6 19.6 ± 4.8 21.5 ± 1.7 20.9
APC
 Cmax (ng/ml) 104 ± 30 112 ± 39 101 ± 28 92 857 ± 312 796 ± 324 901 ± 336 794
 t1/2 (h) 6.3 ± 1.5 5.7 ± 0.5 7.0 ± 1.9 5.3 6.4 ± 1.7 6.4 ± 1.6 5.9 ± 1.0 8.4
 AUC (ng/ml h) 1327 ± 538 1063 ± 220 1549 ± 656 1095 10073 ± 3581 8466 ± 5095 10398 ± 3459 11345
SN-38
 Cmax (ng/ml) 15.5 ± 10.0 14.9 ± 3.2 15.2 ± 13.7 18.2 20.9 ± 12.3 18.7 ± 5.3 21.8 ± 15.9 21.2
 t1/2 (h) 18.8 ± 19.2 16.3 ± 5.2 21.9 ± 26.4 12.7 17.3 ± 10.4 16.9 ± 4.1 14.4 ± 7.4 28.0
 AUC (ng/ml h) 207 ± 141 141 ± 22 248 ± 184 207 212 ± 89 180 ± 57 203 ± 94 291
SN-38G
 Cmax (ng/ml) 43.7 ± 22.3 56.6 ± 20.4 38.6 ± 23.8 31.9 133 ± 62 109 ± 80 145 ± 65 126
 t1/2 (h) 11.7 ± 2.8 11.0 ± 2.5 12.5 ± 3.2 10.4 12.7 ± 5.2 14.0 ± 3.4 11.2 ± 4.9 16.0
 AUC (ng/ml h) 580 ± 377 550 ± 221 658 ± 482 340 1314 ± 604 1119 ± 1054 1305 ± 487 1635
a

Mean value only is listed for 7/7 variant, as n = 2